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Abstract 
Background 
Crohn’s anal fistula should be managed with a multidisciplinary team. There is no clearly 
defined ‘patient pathway’ from presentation to treatment. The aim of this study was to 
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describe the patient route from presentation with symptomatic Crohn’s anal fistula to 
starting anti-TNF therapy. 
 
Method  
Case note review was undertaken at three hospitals with established IBD services. Patients 
with Crohn’s anal fistula presenting between 2010 and 2015 were identified through clinical 
coding and local databases. Baseline demographics were captured. Patient records were 
interrogated to identify route of access, and clinical contacts during the patient pathway.   
 
Results 
79 patients were included in the study, of whom 54 (68%) had an established diagnosis of 
Crohn’s disease. Median time from presentation to anti-TNF therapy was 204 days  (174 
days vs 365 days for existing and new diagnosis of Crohn’s disease respectively (p=0.019)). 
The mean number of surgical outpatients attendances, operations and MRI scans per 
patient was 1.03, 1.71 and 1.03 respectively. Patients attended a mean of 1.49 medical 
clinics. Seton insertion was the most common procedure, accounting for 48.6% of all 
operations. Where care episodes ('clinical events per 30 days') were infrequent this 
correlated with prolongation of the pathway (r = -0.87,p<0.01). 
 
Discussion 
This study highlights two key challenges in the treatment pathway: i) delays in diagnosis of 
underlying Crohn’s disease in patients with anal fistula, ii) the pathway to anti-TNF therapy 
is long, suggesting issues with service design and delivery. These should be addressed to 
improve patient experience and outcome. 
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What does this paper add to the literature? 
This study shows that patients may have delays in their treatment pathway, with most 
patients waiting at least 6 months for medical therapy – this is a novel finding. It also 
highlights the challenges in recognition of Crohn’s disease when anal fistula is the first 
presentation.  
 
Background 
The management of fistulating perianal Crohn’s disease is complex. Patients present in 
many different ways including as an emergency with perianal abscess, or with more chronic 
undulant symptoms or with intractable perianal sepsis1. Recognition of Crohn’s disease in 
patients who present with a perianal fistula can be difficult and effective management is 
challenging. It is generally accepted that control of perianal sepsis and early anti-tumour 
necrosis factor-α (anti-TNFα) therapy is the mainstay of management2. Patients report a 
high level of disability, leading its prominence in recent patient research prioritisation 
exercises3,4.  
 
A patient pathway is a process or sequence of events where a patient is taken from referral 
or first related clinical activity through to treatment5. These have been used in settings such 
as laparoscopic cholecystectomy6, complex biliary disease7 and oesophageal cancer8 and 
achieve more efficient use of resources with lower costs of care.  
The pathway of a patient with Crohn’s anal fistula may involve primary care physicians, 
surgeons, gastroenterologists, radiologists and inflammatory bowel disease nurse specialists 
across outpatient and surgical theatre settings. Even with optimal combined therapy, 
healing of Crohn’s fistulae is reported to be less than 30%9.  
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Given the reported debility, it is likely that delays within this pathway will affect quality of 
life and influence the effectiveness of therapy.  
 
Aim 
The primary aim of the study was to explore the pathway from presentation with 
symptomatic Crohn’s anal fistula to treatment with anti-TNF therapy in specialist hospitals 
with the secondary aim of identifying areas for pathway improvement. 
 
Method 
Three teaching hospitals with large Inflammatory Bowel Disease (IBD) services participated 
in this study. Hospital administrative databases were searched using ICD-9 clinical codes 
K50.x (Crohn’s disease) AND K60.x OR K61 (anal fistula), for events between 2010 and 2015. 
Identified cases were cross-checked against local biologic therapy databases to confirm 
which patients had received anti-TNF treatment. Patient records were retrieved for 
identified cases. 
Adults with newly symptomatic Crohn’s anal fistula not on anti-TNF therapy at the start of 
the study period, and who had received anti-TNF therapy by the end of the study period, 
were included. Those with non-fistulating perianal manifestations of disease, those who 
declined anti-TNF therapy, those already established on anti-TNF therapy, and those who 
transferred care from one hospital to another during the study, were excluded. 
 
Demographic and clinical data extracted from clinical records included: time since diagnosis 
of Crohn’s disease, and prior anti-TNFα, thiopurine or methotrexate use. Crohn’s disease 
phenotype was classified according to Montreal criteria10. 
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Pathway data extracted included: date of first presentation with symptomatic fistula within 
the study period, date of first anti-TNFα dose, date and location of all IBD-related 
documented clinical interactions (outpatient/inpatient), date of MRI scans, and the date and 
nature of any surgical procedures.  
 
Overall pathway length was calculated as time from first presentation to time of first dose 
of anti-TNF in days. Clinical events identified included attendance at surgical and medical 
outpatient clinics, MRI scans, admissions, and surgical procedures. Time to transition from 
each care event (i.e. medical outpatients, surgical outpatients, medical admissions, 
radiology (MRI), elective theatre) was for each event in days. Mean number of events per 
pathway was calculated, as was the rate of care events and unplanned readmission per 30 
days of pathway (care events/(pathway length/30). These values were plotted following log 
transformation to normalise the distribution. 
 
Comparison of medians between groups was performed using Mann-Whitney U-test. Other 
statistical tests used are indicated in parenthesis. A p value of <0.05 was set as the threshold 
for statistical significance a priori. This study was registered as a service evaluation with 
audit departments at respective hospitals.  
 
Results 
Clinical coding identified a total of 311 cases across all sites. Following removal of duplicates 
and excluded cases, a total of 79 (25.4%) of patients were eligible for the study. These were 
split 24/23/32 across the three sites. 
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Clinical characteristics 
54 patients (68%) had a pre-existing diagnosis of Crohn’s disease (CD). The date of diagnosis 
was confirmed from clinical records. In these patients, the mean time from diagnosis of CD 
to presentation in this study was 9.5 years (S.D.+/-7.2). Patient phenotype is presented in 
table 1. Of the 54 patients with a prior diagnosis of CD, 14 (25.9%) had previously received 
anti-TNFα therapy, 27 (50.0%) had previously received thiopurine agents, and 1 (1.8%) 
methotrexate. 
 
Interval between presentation and anti-TNF treatment 
The median time from presentation of a symptomatic Crohn’s fistula to receiving the first 
dose of anti-TNF therapy was 204 days IQR 113-453 days) (Figure 1) across the whole 
cohort. The median interval for patients with existing CD was 174 days compared to 365 
days for those with a new diagnosis of CD (p=0.019).  There was no significant difference in 
the length of the pathway in those patients with a pre-existing diagnosis of CD according to 
whether they had previously received anti-TNF agents or were naïve to them (median 136 
vs 199 days respectively, p=0.29). 
 
Number of care events per 30 days underwent log transformation. Longer pathways showed 
a negative correlation with the number of clinical events per 30 days of the pathway 
(Spearman r = -0.87, (-0.91 to -0.79) p<0.01) and with unplanned readmissions Spearman r = 
-0.95 (-0.97 to -0.91) p<0.01. 
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Route of access and outpatient use 
Overall, 29 of 79 (36.7%) patients initially presented via an acute surgical route, 5 0f 79 
(6.3%) presented via a medical admissions unit, 21 of 79 (26.6%) and 22 of 79 (27.8%) via 
surgical outpatients and medical outpatients respectively, and 2 of 79 (2.5%) presented 
through contact with an IBD specialist nurse. For those 25 patients with no prior diagnosis of 
CD, 9 (36.0%) presented via surgical outpatients and 9 (36.0%) as an acute surgical 
admission. 7 (28.0%) patients presented through medical outpatients. The distribution of 
point of access by diagnosis is detailed in Table 1. The mean number of surgical outpatient 
events per patient was 1.10 across the pathway, and occurred at a mean rate of 0.17 
(S.D.+/-0.19) per 30 days of pathway. The mean number of medical outpatient events per 
patient was 1.49, and occurred at a mean rate of 0.28 per 30 days of the pathway (S.D. +/-
0.40).  
 
Frequency of MRI scanning 
An MRI was performed in 59 (74.6%) of patients during the pathway. Of those undergoing 
MRI, 42 (71.1%) underwent one scan, 15 (25.4%) patients underwent two MRI scans. The 
mean number of MRI was 1.03 per patient, and occurred at a mean rate of 0.43 per 30 days 
of the pathway (S.D. +/-1.01). 
 
Frequency of surgical interventions 
Of the 79 patients, 72 (91.0%) underwent a total of 140 surgical procedures, including 
examination under anaesthetic, seton insertion, drainage of sepsis only, or other fistula 
procedures (Table 2). Of these, 36 (50.0%) had a single procedure, 17 (23.6%) had two 
procedures, 6 (8.3%) had three procedures, 13 (18.0%) had four procedures. The mean 
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number of operations was 1.9 per patient, and occurred at a mean rate of 0.54 per 30 days 
of the pathway (S.D. +/-1.09). 
 
Time to transition 
Time to and from each point of care (medical or surgical outpatients, medical or surgical 
admission, nurse specialist appointments, MRI scans and elective theatres) was calculated. 
Transition from medical outpatients or admission to surgical outpatients tended to be 
shorter than transition from surgical admission or outpatients to medical outpatients (32.0 
vs 56.5 days; p = 0.08) (Table 3). The median time to commencement of anti-TNF from last 
clinic appointment was 77 days (IQR 27.5-225.5 days). 
 
Establishing Current Pathways 
Based upon this data, there are 3 potential clinical pathways from presentation of perianal 
Crohn’s disease to anti-TNF therapy.  The pathways are essentially determined by mode of 
presentation.  
 
Surgical outpatient presentation 
Patients presenting to surgical outpatients tend to undergo elective surgery (median wait 22 
days), followed by attendance at medical outpatients (median wait 48.5 days). Most then 
undergo an MRI (median wait of 34 days) then return to medical outpatients (median wait 
29 days). After this, patients will be started on anti-TNF therapy (median wait 77 days).   
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Emergency surgery presentation 
Patients entering the pathway via acute surgical admission will undergo MRI (median wait 
29.5 days), before attending for surgical follow up (median wait 42 days) and undergoing 
elective surgery (median wait 22 days), and then attending medical outpatients (median 
wait 48.5 days) and accessing anti-TNF therapy (median wait 77 days).  
 
 Medical outpatient presentation 
Finally, patients may present to medical outpatients and be referred for an MRI (median 
wait 34 days), before referral for a surgical opinion (median wait 42 days) and undergoing 
elective surgery (median wait 22 days). They may then proceed to anti-TNF therapy (median 
wait 77 days) (see figure 1).  
 
It is important to note that these reflect frequently represented pathways for the whole 
cohort, and sequences may vary. As suggested by above findings, some patients will have 
multiple clinic appointments and multiple MRI scans. Patients presenting to the surgeons as 
an emergency typically underwent outpatient MRI scan, although a small number 
underwent emergency examination under anaesthesia, with same day discharge and 
outpatient imaging.  
 
Discussion 
This is the first study to assess the patient pathway in patients with perianal Crohn’s 
disease. It has shown that the median pathway length is substantial, even in centres with an 
established IBD service.  There is median delay of 204 days (174 days for patients with 
known CD, and 365 days for new presentations).   
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This work identifies two areas, which if improved, could shorten the patient pathway.  
Firstly, the need to diagnose Crohn’s disease in a newly diagnosed fistula and secondly, the 
need for very close collaboration between medical and surgical teams. 
Perianal fistula may be the first presentation of Crohn’s disease in 15% of patients11. Some 
presentations of perianal disease may be immediately apparent as Crohn’s disease.  There 
may be clinical features typical of Crohn’s disease such as florid oedematous skin tags, 
multiple fistulae and proctitis.  In others without these features, patients may be treated 
initially as having cryptoglandular disease. There is currently no other diagnostic tool 
allowing early identification of disease Crohn’s disease. It is therefore important to ensure 
that symptoms of intestinal disease and a family history of inflammatory bowel disease are 
sought and further investigated.  
Acute perianal abscesses, presenting as an emergency, may be treated by a less experienced 
junior surgeon, possibly with limited senior input and sometimes minimal follow up again 
which may contribute to delays in the pathway. 
 
Patients with suspected Crohn’s disease do not have the enhanced pathways available to 
patients with suspected cancer, and yet a rapidly progressive disease process may mean 
that, by the time of clinical review, return to an earlier point in the pathway may be needed 
- for example, further urgent surgery to drain recurrent infection or repeat MRI scan to 
assess new fistulae. Even with an uncomplicated disease pathway, delayed medical, 
radiological and surgical review or intervention will have an adverse impact on quality of 
life, potentially on long-term outcomes and the likelihood of successful treatment.   
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Options to reduce the delays at each of these steps should be considered. This could include 
agreed fast track referral pathways between medical and surgical arms of the IBD service, 
including directly into surgical admissions units and then back to receive anti-TNFα 
infusions. Combined in-patient rounds and out-patient clinics are likely to help precision of 
diagnosis and appropriate decision-making.  There may be delays relating to screening for 
underlying occult or latent infection, the need to repeat indeterminate TB screening tests 
and capacity issues in biologic clinics. 
 
The importance of shortening the pathway to anti- TNFα treatment assumes that earlier 
anti-TNFα treatment improves both clinical outcomes and quality of life. Although this is 
established in luminal Crohn’s disease12,13, no trial has tested this hypothesis in perianal 
Crohn’s disease. The duration of fistula presence is a poor prognostic factor, indirectly 
suggesting the benefit of a time-based approach8,14,15. However, given the impact of fistula 
symptoms on quality of life and frequent disease deterioration whilst waiting for the next 
step, a streamlined pathway would seem important. 
 
There are limitations to this work, particularly its retrospective nature.  We have only 
captured the timing of events, not the intention that led to the event, nor have we captured 
factors related to patient choice.  We have also defined the pathway as terminating only 
when anti-TNF therapy has been commenced.  Nevertheless we feel that focusing on this 
element of the treatment pathway is relevant as a surrogate both for the experience of 
these patients in terms of symptomatic disability3,4 and because of the perception that 
delays in treatment may be associated with a poorer outcome – a finding replicated in other 
aspects of Crohn’s disease16,17.  
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There is considerable variation in the pathway to anti-TNF therapy for patients with 
fistulating perianal Crohn’s disease.  In most cases the delay to treatment is substantial.  It is 
very likely that such delays affect both quality of life and overall outcome.  These findings 
could be used to test strategies to reduce delay, or to understand barriers to 
implementation of effective treatments from randomized trials into clinical practice. 
 
Conclusion 
There is delay in many of the elements of the pathway in patients with Crohn’s anal fistula. 
In particular, commencement of anti-TNF therapy is often delayed with new diagnoses of 
Crohn’s disease waiting 365 days and patients with established CD waiting 174 days. 
Diagnosis is a challenge in patients with first presentation of Crohn’s disease.  Resolving 
these delays is important to reduce the debility associated with perianal Crohn’s disease. 
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New CD (n=25) Known CD (n=54) 
Overall  
(n=79) 
Medical 
Outpatients 
7 (28%) 15 (27.8%) 22 (27.8%) 
Acute medical 
admission 
0 5 (9.3%) 5 (6.3%) 
Surgical 
Outpatients 
9 (36.0%) 12 (22.9%) 21  (26.6%) 
Acute surgical 
admission 
9 (36.0%) 20 (37.0%) 29 (36.7%) 
IBD Specialist 
Nurse 
0 2 (3.7%) 2 (2.5%) 
 
Table 1: Number of patients (%) accessing pathway at different points according to  pre-
existing diagnosis of Crohn’s disease. 
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Procedure performed Number (percentage of all procedures) 
Examination under anaesthetic 14 (10.0%) 
Drainage of abscess 39 (27.8%) 
Insertion of seton 67 (47.8%) 
Lay open of fistula 10 (7.1%) 
Anal fistula plug 1 (0.7%) 
Video assisted anal fistula treatment 
(VAAFT) 
1 (0.7%) 
Seton removal 5 (3.5%) 
Stoma formation 2 (1.4%) 
Proctectomy 1 (0.7%) 
 
Table 2: Procedures performed during patient treatment. 
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            To 
From MRI SOPD MOPD MAU SAU CNS 
Elective 
Theatre 
MRI - 42 29 - 19 - - 
SOPD 24 51.5 56 - 59 - 22 
MOPD 34 35 89.5 16 70 43 35 
MAU 24 11 26 - 18 - - 
SAU 29.5 45 75 60 61 - 0 
CNS 16 40 39 18 - - - 
Elective 
Theatre 
- 59 48.5 55.5 38 25 73.5 
 
Table 3: Median time (days) to move from one part of the pathway to the next. Point of 
origin is in the left column, and destination is in the horizontal column. ‘–‘ indicates no 
data available. MRI = Magnetic Resonance Imaging, SOPD = Surgical Outpatient 
Department, MOPD = Medical Outpatient Department, MAU = Medical Admissions Unit, 
SAU = Surgical Admissions Unit, CNS = Clinical Nurse Specialist. 
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Figure 1: Case identification chart and reasons for exclusion 
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Figure 2: Cumulative percentage of patients receiving initial anti-TNF therapy in days 
following start of treatment pathway, split by new and existing diagnoses of Crohn’s 
disease 
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Figure 3: Log transformation of rates per 30 days of pathway for any clinical event, and 
unplanned readmission compared to length of pathway (days). Both show significant 
negative correlation of rates with pathway length. (Clinical event Spearman r = -0.87, (-
0.91 to -0.79) p<0.01; Unplanned readmission Spearman r = -0.95 (-0.97 to -0.91) p<0.01. 
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Figure 4: Typical pathways of patients from presentation with Crohn’s anal fistula to 
commencement of anti-TNF therapy: a) for patients presenting to surgical outpatients, b) 
for patients presented acutely to the surgical team and c) for patients presenting initially 
to the medical outpatient team. Curved arrows are labelled with median waiting times (in 
days) between sequential steps in the pathways described. NB not to scale. 
 
 
 
 
